US009409891B2

(12) **United States Patent**
Hashash et al.

(10) **Patent No.: US 9,409,891 B2**
(45) **Date of Patent: Aug. 9, 2016**

(54) **SOLID FORMS OF AN ANTIVIRAL COMPOUND**

(71) Applicant: **Gilead Sciences, Inc.**, Foster City, CA (US)

(72) Inventors: **Ahmad Hashash**, Shrewsbury, MA (US); **Scott Wolckenhauer**, Redwood City, CA (US); **Bing Shi**, Redwood City, CA (US)

(73) Assignee: **GILEAD PHARMASSET LLC**, Foster City, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 224 days.

(21) Appl. No.: **14/313,877**

(22) Filed: **Jun. 24, 2014**

(65) **Prior Publication Data**

US 2014/0309187 A1 Oct. 16, 2014

Related U.S. Application Data

(63) Continuation of application No. 13/800,991, filed on Mar. 13, 2013, now Pat. No. 8,841,340.

(60) Provisional application No. 61/684,297, filed on Aug. 17, 2012.

(51) **Int. Cl.**

A61K 31/381	(2006.01)
A61K 31/4184	(2006.01)
A61K 31/7056	(2006.01)
A61K 31/7072	(2006.01)
A61K 45/06	(2006.01)
C07D 407/04	(2006.01)
C07D 409/12	(2006.01)
C07D 471/08	(2006.01)

(52) **U.S. Cl.**

CPC ***C07D 409/12*** (2013.01); ***A61K 31/381*** (2013.01); ***A61K 31/4184*** (2013.01); ***A61K 31/7056*** (2013.01); ***A61K 31/7072*** (2013.01); ***A61K 45/06*** (2013.01); ***C07D 407/04*** (2013.01); ***C07D 471/08*** (2013.01)

(58) **Field of Classification Search**

CPC A61K 31/381; A61K 31/4184; A61K 31/7056; A61K 31/7072; A61K 45/06; C07D 407/04; C07D 409/12; C07D 471/08

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,861,421	A	1/1999	Christensen, IV et al.
6,881,741	B2	4/2005	Chan Chun Kong et al.
6,887,877	B2	5/2005	Chan Chun Kong et al.
7,402,608	B2	7/2008	Chan Chun Kong et al.
7,521,473	B2	4/2009	Lee et al.
7,569,600	B2	8/2009	Denis et al.
8,501,714	B2	8/2013	Cho et al.
8,524,764	B2	9/2013	Canales et al.
8,569,302	B2	10/2013	Canales et al.
8,741,946	B2	6/2014	Watkins et al.
8,759,544	B2	6/2014	Evans et al.
8,765,722	B2	7/2014	Cho et al.
2002/0002199	A1	1/2002	Jeppesen et al.
2003/0229053	A1	12/2003	Chan Chun Kong et al.
2004/0116509	A1	6/2004	Chan Chun Kong et al.
2005/0119332	A1	6/2005	Jeppesen et al.
2006/0142347	A1	6/2006	Chan Chun Kong et al.
2006/0276533	A1	12/2006	Denis et al.
2007/0099929	A1	5/2007	Thede et al.
2008/0299080	A1	12/2008	Chan Chun Kong et al.
2009/0274655	A1	11/2009	Grimes et al.
2011/0020278	A1	1/2011	Canales et al.
2011/0178058	A1	7/2011	Canales et al.
2011/0178129	A1	7/2011	Canales et al.
2013/0052161	A1	2/2013	Watkins et al.
2013/0315861	A1	11/2013	Canales et al.
2013/0323203	A1	12/2013	Canales et al.

(Continued)

FOREIGN PATENT DOCUMENTS

WO	02/100846	A1	12/2002
WO	02/100851	A2	12/2002

(Continued)

OTHER PUBLICATIONS

U.S. Appl. No. 12/838,684, filed Jul. 19, 2010.
U.S. Appl. No. 13/006,761, filed Jan. 14, 2011.
U.S. Appl. No. 13/007,150, filed Jan. 14, 2011.
U.S. Appl. No. 13/392,467, filed Mar. 13, 2012.
U.S. Appl. No. 13/549,130, filed Jul. 13, 2012.
U.S. Appl. No. 13/800,991, filed Mar. 13, 2013.
U.S. Appl. No. 13/801,011, filed Mar. 13, 2013.
U.S. Appl. No. 14/037,296, filed Sep. 25, 2013.
U.S. Appl. No. 13/927,355, filed Jun. 26, 2013.
U.S. Appl. No. 13/958,424, filed Aug. 2, 2013.
U.S. Appl. No. 13/939,695, filed Jul. 11, 2013.

(Continued)

Primary Examiner — Kendra D Carter

(57) **ABSTRACT**

Crystalline solid forms and the amorphous form of the anti-HCV compound 5-(3,3-dimethylbutyn-1-yl)-3-[(cis-4-hydroxy-4-{[(3S)-tetrahydrofuran-3-yloxy]methyl}cyclohexyl){[(1R)-4-methylcyclohex-3-en-1-yl]carbonyl}amino]thiophene-2-carboxylic acid (Compound I) were prepared and characterized in the solid state:

Compound I



Also provided are processes of manufacture and methods of using the crystalline forms.

24 Claims, 28 Drawing Sheets